TEL AVIV, Israel and BETHESDA, Maryland, Jan. 22, 2019 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that Mr. Eyal Barad, Co-Founder and CEO, and Dr. Eyal Ballan, Co-Founder and CTO, will be in Davos, Switzerland in January, 2019. They will attend the World Economic Conference as part of the CannaTech Davos at Canada Cannabis House Pavilion, hosted in collaboration with the Canadian Securities Exchange and OTC Markets.
Cannabics CEO Eyal Barad will be featured in the panel “Exporting Cannabis Innovation to the World from Israel” Forum, on Thursday January 24th, from 4:00pm to 6:00pm.
“We are pleased to be attending an event of this global scale, which affords us the opportunity of presenting our technology one on one to world leaders and the most highly respected group of political, NGO and business executives”, said Mr. Eyal Barad. “We hope to be able to leverage our participation in the Forum to bring to light the importance of Cannabis both economically and therapeutically and continue our mission of bringing Cannabinoid based therapies to regulated modern medicine.”
The Canada Cannabis House will feature sessions with distinguished group of speakers, including Mr. Ehud Barak, Former Israeli Prime Minister and Chairman of InterCure; as well as Mr. Roei Zerahia, CEO of Canndoc; Mr. Yona Levy, CEO of Alvit and Tefen; Mr. Lorne Gertner, Chairman of Hiku Brands; Mr. Jason Warnock, CEO of TheraCann; and Mr. Saul Kaye, CEO of iCAN, Israel Cannabis.
Saul Kaye noted, “I am thrilled that CannaTech will be co-hosting the Canada Cannabis House along with the Canadian Securities Exchange (CSE), OTC markets, and Kapoor Capital in Davos. It is an honor to participate in Davos and help regulators and industry giants understand the impact of this emerging industry on a global level.
“The emerging cannabis industry is poised to revolutionize patient care, and these changes are creating new global ecosystems poised to have a positive impact with new treatments. Cannabis is part and parcel of the next wave of globalization and a serious discussion in Davos could not be more timely,” said iCAN’s CEO and Founder, Mr. Saul Kaye.
About CannaTech
CannaTech is the world’s premier medical cannabis event. As a globally renowned platform for education, innovation, and acceleration, CannaTech showcases the brightest minds in the cannabis industry. Events are hosted around the world, offering a unique opportunity to engage with experts and pioneers in the fields of finance, science, government policy, ag-tech and more.
About Cannabics Pharmaceuticals
Headquartered in Tel-Aviv, Israel, Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals and LinkedIn .
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 17th, 2019. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
